Valid for Submission
Z19.1 is a billable diagnosis code used to specify a medical diagnosis of hormone sensitive malignancy status. The code Z19.1 is valid during the fiscal year 2022 from October 01, 2021 through September 30, 2022 for the submission of HIPAA-covered transactions.
The ICD-10-CM code Z19.1 might also be used to specify conditions or terms like hormone sensitive prostate cancer. The code is exempt from present on admission (POA) reporting for inpatient admissions to general acute care hospitals.
The code Z19.1 describes a circumstance which influences the patient's health status but not a current illness or injury. The code is unacceptable as a principal diagnosis.
Index to Diseases and Injuries
The Index to Diseases and Injuries is an alphabetical listing of medical terms, with each term mapped to one or more ICD-10 code(s). The following references for the code Z19.1 are found in the index:
The Medicare Code Editor (MCE) detects and reports errors in the coding of claims data. The following ICD-10 Code Edits are applicable to this code:
The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:
- Hormone sensitive prostate cancer
Present on Admission (POA)
Z191 replaces the following previously assigned ICD-10 code(s):